瑞卡西单抗单药治疗非家族性高胆固醇血症和混合性高脂血症:3期REMAIN-1随机试验
REMAIN-1是一项在中国59个中心开展的随机、双盲、安慰剂对照3期研究,纳入703例非家族性高胆固醇血症和混合性高脂血症、ASCVD低中危患者,评估瑞卡西单抗三种给药方案单药治疗的疗效与安全性。结果显示,与安慰剂相比,瑞卡西单抗150 mg Q4W、300 mg Q8W和450 mg Q12W分别进一步降低LDL-C 49.6%、52.8%和45.0%(P均<0.0001),安全性与你安慰剂相当。
要点
- 瑞卡西单抗三种给药方案(Q4W、Q8W、Q12W)均显著降低LDL-C,降幅45.0%-52.8%。
- 安全性与你安慰剂相当,最常见治疗相关不良事件为注射部位反应(4.9%)。
- 支持最长每12周一次给药,为患者提供灵活给药选择。
核心结论
- 瑞卡西单抗单药治疗可显著降低非家族性高胆固醇血症和混合性高脂血症、ASCVD低中危患者的LDL-C,且安全性与你安慰剂相当,给药间隔可长达Q12W。
研究设计与样本
- 随机、双盲、安慰剂对照3期研究,在中国59个中心开展。
- 纳入空腹LDL-C ≥2.6至<4.9 mmol/L、空腹甘油三酯≤5.6 mmol/L、10年ASCVD风险评分<10%的患者。
- 703例患者随机分配(2:2:2:1:1:1)接受瑞卡西单抗150 mg Q4W、300 mg Q8W、450 mg Q12W或匹配安慰剂皮下注射,背景为降脂饮食。
主要发现
- 主要终点:与安慰剂相比,瑞卡西单抗150 mg Q4W在12周时进一步降低LDL-C 49.6%(95%CI:44.2%-54.9%)。
- 300 mg Q8W在16周时进一步降低LDL-C 52.8%(95%CI:48.3%-57.2%)。
- 450 mg Q12W在12周时进一步降低LDL-C 45.0%(95%CI:41.0%-49.0%)。
- 所有比较P<0.0001。
- 24周瑞卡西单抗治疗及安慰剂转换至瑞卡西单抗后均有效;最常见治疗相关不良事件为注射部位反应(n=23,4.9%)。
临床怎么用
- 对于ASCVD低中危的非家族性高胆固醇血症和混合性高脂血症患者,可考虑瑞卡西单抗单药治疗,给药方案包括150 mg Q4W、300 mg Q8W或450 mg Q12W。
- 最长每12周一次给药可提高依从性,但需注意注射部位反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have been used to reduce the level of low-density lipoprotein cholesterol (LDL-C), but require either biweekly or monthly dosing frequency. Recaticimab is a new humanized monoclonal antibody selectively targeting PCSK9, with long-acting characteristic. OBJECTIVES: The purpose of this study was to assess the efficacy and safety of recaticimab monotherapy in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, and to explore different dosing strategies to provide patients with flexible administration options. METHODS: This was a randomized, double-blind, placebo-controlled, phase 3 study conducted at 59 sites in China. Patients with fasting LDL-C ≥2.6 to <4.9 mmol/L, fasting triglyceride ≤5.6 mmol/L, and 10-year ASCVD risk score <10% were randomly assigned (2:2:2:1:1:1) to receive subcutaneous injections of recaticimab at 150 mg every 4 weeks (Q4W), 300 mg every 8 weeks (Q8W), or 450 mg every 12 weeks (Q12W), or matching placebo, on background lipid-lowering diet. Primary endpoint was percentage change in LDL-C from baseline to week 12 for 150 mg Q4W and 450 mg Q12W and to week 16 for 300 mg Q8W. RESULTS: A total of 703 patients underwent randomization and received recaticimab (n = 157, 156, and 155 for 150 mg Q4W, 300 mg Q8W, and 450 mg Q12W, respectively) or placebo (n = 78, 79, and 78, respectively). Compared with placebo, recaticimab further reduced LDL-C by 49.6% (95% CI: 44.2%-54.9%) at 150 mg Q4W, 52.8% (95% CI: 48.3%-57.2%) at 300 mg Q8W, and 45.0% (95% CI: 41.0%-49.0%) at 450 mg Q12W (P < 0.0001 for all comparisons). Safety with recaticimab was comparable to placebo. After 12 or 16 weeks of treatment, patients who received recaticimab continued treatment until week 24, whereas those allocated to placebo were switched to recaticimab treatment with the same dosing strategy. Both 24-week recaticimab and 12- or 8-week recaticimab switched from placebo were effective. With 24 weeks of recaticimab treatment, the most common treatment-related adverse event was injection site reaction (n = 23 [4.9%]). CONCLUSIONS: Recaticimab monotherapy yielded significant LDL-C reductions and showed comparable safety vs placebo in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate ASCVD risk, even with an infrequent dosing interval up to Q12W.
引用
- Xu M, Wang Z, Zhang Y, et al. Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial. J Am Coll Cardiol. 2024. PMID: 39387764. doi:10.1016/j.jacc.2024.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。